#551Medicine & HealthFront Page4 March 2026
Lepodisiran: The RNA Therapy Targeting a Stubborn Cardiovascular Risk
Researchers are investigating a small interfering RNA drug to directly lower lipoprotein(a), a highly prevalent and independent cardiovascular risk factor. Early trials have assessed the safety and efficacy of this targeted approach, prompting an ongoing Phase 3 trial to measure actual clinical outcomes.
By Urina-Jassir, Tong, Stanisic, Frishman, Aronow
